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Background: Cyclic phosphatidic acid (cPA) potently inhibits neointima formation by inhibiting PPARγ. 
Results: cPA suppressed PPARγ-mediated cell growth and migration in D-HCAECs.  
Conclusion: cPA inhibited VEGF expression resulting in suppressing cell growth and migration in D-
HCAECs. 
Significance: cPA plays a regulatory role of PPARγ in the vascular processes. 
 
 Atherosclerosis is a disease characterized by building up plaques formation and leads to a potentially 
serious condition in which arteries are clogged by fatty substances such as cholesterol. Increasing 
evidence suggests that atherosclerosis is accelerated in type II diabetes. Recent study reported that high 
level of alkyl glycerophosphate (AGP) was accumulated in atherosclerotic lesions. The presence of this 
phospholipid in mildly oxidized low-density lipoprotein (LDL) is likely to be involved in atherogenesis. It 
has been reported that the activation of peroxisome proliferator-activated receptor gamma plays a key role 
in developing atherosclerosis. Our previous result indicates that cyclic phosphatidic acid (cPA), one of 
bioactive lipids, potently suppresses neointima formation by inhibiting the activation of peroxisome 
proliferator-activated receptor gamma (PPARγ). However, the detailed mechanism is still unclear. In this 
study, to elucidate the mechanism of the cPA-PPARγ axis in the coronary artery endothelium, especially 
in patients with type II diabetes, we investigated the proliferation, migration, and secretion of VEGF in 
human coronary artery endothelial cells from diabetes patients (D-HCAECs). AGP induced cell growth 
and migration, however, cPA suppressed the AGP-elicited growth and migration in D-HCAECs. 
Moreover, AGP increased VEGF secretion from D-HCAECs, and this event was attenuated by cPA. 
Taken together, these results suggest that cPA suppresses VEGF-stimulated growth and migration in D-
HCAECs. These findings could be important for regulatory roles of PPARγ and VEGF in the vascular 
processes associated with diabetes and atherosclerosis.  





Atherosclerosis is an inflammatory disease in which lesions or plaques build up in arteries [1] [2]. 
The first step in the development of atherosclerotic lesions is the activation of cells in blood-vessel walls, 
such as endothelial cells [3] [4]. It is well known that the endothelium is directly involved in vascular 
disease, stroke, heart disease, and diabetes [5]. Especially, diabetes has been reported to increase the risk 
of cardiovascular disease by accelerating the formation of atherosclerosis [6]. Diabetes-associated 
atherosclerosis and vascular diseases are the principal causes of morbidity and mortality in patients with 
diabetes [7].  
Lysophosphatidic acid (LPA) is a bioactive lipid that is produced in serum after the activation of 
multiple biochemical pathways [8] [9]. Some clinical studies have reported that the plasma LPA level is 
correlated with vascular diseases and some species of LPA induce neointima formation, which is a 
characteristic feature of common vascular pathologies such as atherosclerosis. However, previous reports 
stated that neointima formation induced by unsaturated LPA is not mediated by LPA1 and LPA2 receptors 
that are the major LPA-receptor subtypes of the G-protein coupled receptors (GPCRs) expressed in blood-
vessel walls [10]. Thus numerous factors contribute to atherosclerosis, a complex disease that is 
accelerated by diabetes and metabolic syndrome. Moreover, because metabolic syndrome occurs 
commonly in people with type II diabetes which most of the increased incidence of cardiovascular 
diseases [11] [12]. 
We previously reported that unsaturated LPA species induced arterial-wall remodeling in rat and 
mouse non-injury model, and this response required peroxisome proliferator-activated receptor gamma 
(PPARγ) [13]. The function of PPARγ has been studied extensively, and a variety of synthetic and 
physiological agonists of this receptor have been identified [14], including thiazolidinediones (TZDs) and 
numerous natural ligands containing fatty acids and phospholipids [14]. Recently, selected phospholipid 
such as LPA and alkyl-glycerophosphate (AGP, also known as alkyl-LPA) were identified as agonists of 
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PPARγ (Fig.1) [15] [16]. Later, we reported that AGP is a specific high-affinity and more potent agonist 
of PPARγ than LPA. Fujiwara and colleagues reported that AGP, an analog of LPA, is a weak agonist of 
LPA receptors except LPA5 receptor, however, only LPA5 receptor shows a preference for AGP than LPA 
[20]. Interestingly, AGP has a higher potency than LPA with respect to PPARγ activation [16]. Binding 
studies using the PPARγ ligand-binding domain showed that binding study of the AGP was similar to that 
of the TZD rosiglitazone [16]. We recently identified cyclic phosphatidic acid (cPA) is an endogenous 
PPARγ antagonist, and it is generated by phospholipase D2 (PLD2) [13]. These observations suggest that 
activation of PPARγ is likely to lead to a complex cellular response.  
Earlier studies have shown that PPARγ, which plays a key role in the cardiovascular system, is 
expressed in all cell types of the blood-vessel wall and in monocytes and macrophages [21]. Coronary 
artery disease is the most common type of heart disease, and the leading cause of death from 
cardiovascular diseases is typically the result of atherosclerosis [22]. Our results thus raise the possibility 
of using cPA as a lead compound to develop new treatments that act on PPARγ. However, the critical 
genes affected by the cPA-mediated inhibition in the endothelial cells of the coronary artery remain 
unknown. The migration of endothelial cells contributes to diverse aspects of vascular physiology such as 
the development of atherosclerosis. Currently, cPA plays a role in the anti-neointima activity of carotid 
arteries [13]; and, thus, it is important to understand the mechanisms that determine cPA sensitivity.  
  Here, we are focusing on the regulation of the vascular endothelial growth factor (VEGF) 
regulation induced by cPA. VEGF is a growth factor that was first identified to be specific to the vascular 
endothelium [23]. In mammals, the VEGF family consists of five members, VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and the placenta growth factor (PLGF) [24]. VEGF is a potent mitogen and angiogenic growth 
factor that is the most critical regulator of vascular development [23]. Previously, VEGF was shown to 
play a role in endothelial cell proliferation, migration, and atherosclerosis [25]. Several studies have 
demonstrated that PPARγ agonists regulate the expression of various genes including VEGF and its 
receptors [26]. Rosiglitazone, one of TZDs and a synthetic agonist of PPARγ, has been reported to 
suppresses VEGF expression through a PPARγ-responsive element in the promoter of the VEGF gene, 
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and pioglitazone, another synthetic agonist of PPARγ, was reported to decrease VEGF expression [27]. 
On the contrary, other studies have reported that TZD drugs increase VEGF expression [26].  
   In diabetes, a key factor could be the potential involvement of VEGF in the development of 
atherosclerosis in patients with diabetes [28]. The discrepancies in the aforementioned results may have 
arisen from the use of distinct cell types, but the exact mechanisms remain unknown. Moreover, although 
cPA can arrest the growth of cells, including diabetic human coronary artery endothelial cells (D-
HCAECs), the relationship between the anti-cell growth effect of cPA and the regulation of VEGF 
expression is unknown. In this study, we determined that the PPARγ antagonist cPA potently inhibited 
the release of VEGF protein into the media which express high levels of PPARγ in D-HCAECs. The 
reduction in VEGF expression and secretion was linked to a decrease in the expression of the mRNA and 
the transcriptional inactivation of the VEGF promoter. We conclude that the inhibition of PPARγ 
downregulates VEGF expression and that this may be involved in the regulation of D-HCAECs 
proliferation and migration.  
 
EXPERIMENTAL PROCEDURES 
Materials – A rabbit polyclonal anti-PPARγ antibody (sc-7196), a mouse monoclonal anti-β-actin 
antibody (sc-47778), a PPARγ small interfering RNA (siRNA) (sc-38304), and a control siRNA (sc-
37007) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). A mouse 
monoclonal VEGF antibody (11081) was purchased from Immuno-Biological Laboratories (Fujioka, 
Gunma, Japan). We obtained cPA (18:1) as a gift from Dr. Kimiko Murakami-Murofushi (Ochanomizu 
University, Tokyo, Japan). AGP (18:1) and LPA (18:1) were purchased from Cayman Chemical 
Company (Ann Arbor, MI, USA). 
 
Cell cultures – Primary human coronary artery endothelial cells (HCAECs) and HCAECs from donors 
with type II diabetes (D-HCAECs) were purchased from Lonza (Walkersville, MD, USA) and propagated 
in endothelial cell growth medium (EBMTM-2, Lonza) containing 5% FBS and manufacturer-
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recommended supplemental growth factors (EGM-2TM BullekitTM), antibiotics, and antimycotics. All 
assays were performed on cells between passages 3 and 12 and were repeated at least 3 times in duplicate 
or triplicate. 
 
Reporter gene assays – PPARγ activation was measured in HCAECs and D-HCAECs transfected with 
125 ng of the pGL3-PPRE-acyl-CoA oxidase luciferase vector, 62.5 ng of the pcDNA3.1-PPARγ vector, 
and 12.5 ng of the pSV-β-galactosidase (Promega) vector, which were constructed as previously reported 
[13,16]. At 24 h after transfection, cells were treated with Opti-MEM (Invitrogen) containing the test 
compounds dissolved in DMSO (up to 0.1%) and cultured for an additional 20 h. Luciferase activity was 
measured using the ONE-Glo Luciferase Assay System (Promega) and a LuMate microplate luminometer 
(Awareness Technology, Inc., Palm City, FL, USA). To monitor the transcriptional regulation of VEGF 
promoter activity, we used the human VEGF gene promoter (–2279 to +54) cloned into the luciferase 
reporter plasmid pGL2 (Promega). Plasmids were amplified in Escherichia coli DH5α (Toyobo, Osaka, 
Japan) and isolated using the FastGene Plasmid Mini Kit (Nippon Genetics, Tokyo, Japan). HCAECs and 
D-HCAECs grown to 70%–80% confluence were transfected in 96-well plates by using 0.5 μL of 
Lipofectamine LTX (Life Technology) and 75 ng of plasmid DNA per well, according to the supplier’s 
protocol. After 24 h, the medium was changed and, where necessary, supplemented with AGP or cPA (1, 
3, or 10 μM). The cells were collected 24 h after incubation, lysed, and subjected to the luciferase assay. 
 
Quantitative real-time PCR analysis – Total RNA was isolated from HCAECs and D-HCAECs by using 
a NucleoSpin® RNA II kit (TAKARA, Otsu, Japan), and 0.5 µg of the RNA was used for the subsequent 
synthesis of cDNA by using a ReverTra Ace qPCR RT Kit (Toyobo) as recommended by the 
manufacturer. The levels of mRNA were measured by using an ECO Real-Time PCR system (Illumina, 
Inc., San Diego, CA, USA) and SYBR Green Real-Time PCR Master Mix -Plus- (Toyobo) with the 
following primer pairs: PPARγ1, 5′–GTGGCCGCAGATTTGAAAGAAG–3′ (Forward) and 5′–
TGTCAACCATGGTCATTTCG–3′ (Reverse); PPARγ2, 5′–CAAACCCCTATTCCA TGCTGTT–3′ (F) 
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and 5′–AATGGCATCTCTGTGTCAACC–3′ (R); LPA1, 5′–ACGGTCATTCCGTATGCAGC–3′ (F) and 
5′–GGATAGCCCCCATGACGAT–3′ (R); LPA2, 5′–TCTTCCTGCTCATGGTGGC–3′ (F) and 5′–
GCGTTGTTTCACGGTAGCG–3′ (R); LPA3, 5′–TCCAACCTCATGGCCTTCTT–3′ (F) and 5′–
GACCCACTCGTATGCGGAGA–3′ (R); LPA4, 5′–ATGCAACCACCACCTGCTTT–3′ (F) and 5′–
AGGAATGATAAAACCAACAACTTCAA–3′ (R); LPA5, 5′–CTCGGTGGTGAGCGTGTACATG–3′ 
(F) and 5′–GCGTAGCGGTCCACGTTGAT–3′ (R); LPA6, 5′–GGCCAAGAGAGTCACAATTCAGG–3′ 
(F) and 5′–CAGCGTCATTATGAGGTCTGC–3′ (R); VEGF-A, 5′-AGGGCAGAATCATCACGAAGT-
3′ (F) and 5′–AGGGTCTCGATTGGATGGCA–3′ (R); 18S rRNA, 5′–
CAGCCACCCGAGATTGAGCA–3′ (F) and 5′–TAGTAGCGACGGGCGGTGTG–3′ (R). All PCRs 
were performed in 10 μL mixtures in 48-well PCR plates (Illumina). The cycling conditions were 95°C 
for 10 min (polymerase activation), followed by 40 cycles of 95°C for 15 s, 55°C for 15 s, and 72°C for 
30 s. To identify the housekeeping genes that were most suitable for normalizing the data, we initially 
used a human housekeeping gene primer set (TAKARA). After amplification, the samples were slowly 
heated from 55°C to 95°C and fluorescence was measured continuously to obtain a melting curve. The 
relative mRNA levels were quantified by using the formula 2-ΔΔCq, where ΔCq is the difference between 
the threshold cycle of a target cDNA and an endogenous reference cDNA. 
 
Small interfering RNAs – The expression of PPARγ and VEGF in HCAECs and D-HCAECs was 
inhibited by transfecting with siRNAs targeted to PPARγ and VEGF (Santa Cruz Biotechnology) by 
using Lipofectamine RNAiMAX (Invitrogen). Cells were cultured in 6-well plates (Iwaki, Tokyo, Japan) 
at a density of 5 × 104 cells/well in DMEM containing 10% FBS. Cells were transfected with 100 
pmol/mL of mRNA-specific siRNAs or a scrambled control siRNA. The reduction in PPARγ levels was 
confirmed using western blotting analysis. 
 
Measurement of cell proliferation – HCAECs and D-HCAECs were seeded in 96-well culture plates (5 × 
103 cells/well), and cell proliferation was determined using the Cell Counting Kit-8 (Dojindo, Kumamoto, 
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Japan). After cells were incubated for 24 h, 10 μL of the Cell Counting Kit-8 solution was added to each 
well and the plates were incubated for 2 h in an incubator at 37°C with 5% CO2. The amount of orange 
formazan dye was determined by measuring the absorbance at 450 nm in a microplate reader (Awareness 
Technology). 
 
Wound-healing assay – Cell-migration assays were performed using μ-Dish 35 mm culture inserts (Ibidi, 
Martinsried, Germany) according to the manufacturer’s protocols. Briefly, D-HCAECs (1.4 × 104 
cells/well) were seeded into each well of the culture inserts and incubated at 37°C. After the cells were 
attached, the culture inserts were gently removed, and the cells were treated with 2% FBS containing 
fresh medium supplemented with the vehicle, AGP, cPA, or the synthetic PPARγ antagonist T0070907. 
Immediately after removing the inserts (0 h) and at 3 and 6 h, cultures were photographed using phase-
contrast microscopy, and the widths of wounds were measured to calculate the mean percentage of 
closure under each culture condition. 
 
Assessment of VEGF secretion by D-HCAECs and HCAECs in vitro – Cells were seeded in 60 mm dishes 
at a density of 5 × 104 cells/dish and incubated in 10% FBS containing medium overnight, followed by 
incubation in serum-free medium for 24 h. Levels of human VEGF in the samples were determined by 
performing a sandwich enzyme immunoassay by using a human VEGF Assay Kit-IBL (Immuno-
Biological Laboratories, Fujioka, Japan). 
 




Humans express two PPARγ isoforms, PPARγ1 and PPARγ2 originated from alternative splicing 
[29]. We first examined the mRNA expression level of PPARγ1 and PPARγ2 in HCAECs and D-HCAECs. 
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As shown in Figure 2A, PPARγ1 mRNA was expressed at higher levels in D-HCAECs than in HCAECs. 
In contrast to PPARγ1, we did not detect the expression of PPARγ2 mRNA in the both cell types/lines. We 
next investigated PPARγ protein expression levels in the cells (Fig. 2B). We observed that the two 
primary cell lines expressed distinct levels of PPARγ1, however, PPARγ2 was hardly detectable. The 
expression levels of PPARγ1 and PPARγ2 proteins agreed well with those of the mRNAs expression.  
 
 
However, in D-HCAECs, treatment with AGP and cPA did not alter PPARγ mRNA expression 
for 24 h (Fig. 3B). To test the function of the PPARγ receptor, we transfected the cells with a luciferase 
reporter plasmid. Interestingly, luciferase activity increased only in D-HCAECs after exposure to AGP 
(Fig.3C). Next, to establish that none of the six known LPA receptors (LPA1-6) is required for activation 
of PPARγ, we confirmed the expression levels of LPA1-6 mRNAs in HCAECs and D-HCAECs. As shown 
in Figure 3C, only LPA4 mRNA was highly expressed in the two cell lines, and the expression of this 
receptor in D-HCAECs was significantly greater than that in HCAECs. To examine the differences in 
LPA4 activation in response to cPA and AGP, we obtained full dose-response curves of the activation of 
LPA4 by cPA and AGP in D-HCAECs. Previous report suggested that cPA is a weak agonist of LPA4 and 
it has a significantly higher EC50 than LPA and AGP [30]. Furthermore, the endogenous PPARγ 
antagonist cPA inhibited the enhanced activation of PPARγ activation elicited by AGP. We found that 
these two cell types expresse high levels of LPA4 (Fig. 3D). For this reason, we also tested the ligand 
properties of AGP (18:1) and cPA (18:1) on LPA4. As shown in Fig. 3D, although AGP 18:1 activated 
LPA4, cPA 18:1 was no response up to 10 μM in LPA4 overexpressing cells. These results suggest that 
cPA might not be associated with LPA4 receptor in D-HCAEC cells.  
We next investigated the effect of the growth properties of HCAECs. As shown in Figure 4A, D-
HCAECs obtained from diabetic donors grew faster than the HCAECs obtained from healthy donors; D-
HCAEC cell numbers were significantly higher than HCAEC cell after 24 h incubation using medium 
containing 5% FBS and the manufacturer-recommend supplemental growth factors. We next investigated 
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the effect of cPA on the growth in HCAECs. cPA did not affect on the growth in HCAECs (Fig.4B). 
however, cPA induced cell growth in a time-dependent manner in D-HCAECs (Fig.4C). D-HCAECs 
showed more responsive to cPA than HCAECs (Figs. 4B and 4C). These data suggest that the altered 
growth properties of the cells obtained from the diabetic donors may represent a requisite feature of the 
diabetic status. To evaluate how PPARγ affects the growth of D-HCAECs, PPARγ expression was 
knocked down using siRNAs (Fig.4F) (it should be 4D). PPARγ-siRNA efficiently reduced the protein 
expression (Fig.4X). As shown in Figure 4D, and 4E, cell growth increased after transfection with 
PPARγ-siRNA, an effect that was not observed using the control siRNA. These results demonstrate that 
cPA-mediated inhibition of cell growth is PPARγ-dependent and indicate that D-HCAECs are more 
sensitive to cPA-induced growth inhibition than control HCAECs. To characterize the biological role of 
cPA-dependent inhibition of D-HCAEC growth, we determined the effect of the inhibition on the 
migration of D-HCAECs in a wound-healing assay. After the cells were attached, culture inserts were 
gently removed, and the cells were treated with fresh medium containing 2% FBS and photographed over 
the next 6 h to measure wound widths. Representative results are shown in Figure 5A, which demonstrate 
that D-HCAECs migrated markedly faster than HCAECs after a 6 h subculture. To determine whether 
cPA affects D-HCAEC migration, we cultured D-HCAECs in the presence of vehicle, AGP, cPA, or 
T0070907 and photographed the cells over the next 6 h to measure wound widths. Our results showed 
that AGP, but not cPA, strongly induced D-HCAEC migration (Fig. 5B). Furthermore, the synthetic 
PPARγ antagonist T0070907 strongly inhibited cell migration. To evaluate the effects of PPARγ on the 
migration of D-HCAECs, PPARγ expression was knocked down using siRNAs. As shown in Figure 5C, 
cell migration increased after transfection with the siRNA targeting PPARγ but not the control siRNA. 
These results suggest that PPARγ inhibition strongly influences D-HCAEC migration. 
VEGF is a potent inducer of endothelial cell proliferation and migration [31]. Noteworthy, VEGF 
also induces expression of IL-6, and IL-8 in endothelial cell [32] [33].  We performed real-time PCR 
analysis to determine whether lysophospholipids PPARγ ligands affects the levels of VEGF mRNA in 
vitro. As shown in Fig. 6A, VEGF mRNA levels in D-HCAECs were markedly enhanced after treatment 
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with 1 μM AGP and further increased when 10 μM AGP was added; these are the concentrations of AGP 
that are present physiologically [16]. Furthermore, LPA also increased VEGF mRNA levels in D-
HCAECs in a dose-dependent manner (Fig. 6A). Interestingly, real-time PCR analysis revealed that, in D-
HCAECs, cPA decreased VEGF mRNA expression (Fig.6A). To determine how VEGF secretion is 
stimulated, HCAECs and D-HCAECs were incubated in the absence or presence of 1, 3, and 10 μM AGP 
and then conditioned media were assayed for secreted VEGF by performing ELISAs. As shown in Fig. 
6B, AGP were significantly increased VEGF secretion dose-dependently in D-HCAECs.  
Representative results are shown in Figure 6C, which demonstrate that AGP and LPA but not cPA 
strongly induced VEGF secretion by D-HCAECs; cPA at concentrations as high as 1, 3, and 10 μM failed 
to induce VEGF secretion, whereas AGP and LPA increased VEGF secretion by D-HCAECs in a dose-
dependent manner (Fig. 6C). These data suggest that exogenously applied cPA inhibited VEGF secretion 
elicited by LPA or AGP. Next, we determined effect of PPARγ ligands on the activity of the VEGF gene 
promoter (Fig. 6D). The cells were transfected with a reporter plasmid containing the VEGF promoter 
and then incubated with AGP or cPA. In D-HCAECs, the promoter activity was substantially enhanced 
compared with that in HCAECs after treatment with AGP but not cPA. Intriguingly, cPA inhibited the 
VEGF-promoter activation induced by AGP.  
These data suggest that the effect of the PPARγ antagonist cPA on VEGF mRNA expression is 
mediated at least partly by a decrease in the rate of transcription from the VEGF promoter. We also 
explored the influence of VEGF per se on the growth of D-HCAECs. As shown in Figure 6E, cPA 
inhibited exogenously added VEGF enhanced D-HCAEC growth. Furthermore, transfection of D-
HCAECs with control or VEGF siRNA revealed that the VEGF knockdown (Fig.7A and B) attenuated 
AGP-induced VEGF secretion (Fig. 7C) and cell growth promotion (Fig. 7D). Furthermore, as shown in 








Diabetes patients have been reported to have a 2- to 4-fold increased risk of developing 
atherosclerotic coronary artery disease [34]. Endothelial dysfunction has been suggested to be an early 
event in diabetic atherosclerosis, and this dysfunction is associated with atherosclerotic coronary artery 
disease risk [35]. Brief exposure to AGP has been reported to induce progressive neointima formation 
[10] and, recently, LPA and its analog were shown to stimulate a new type of signaling by directly 
activating PPARγ [15]. A previous report suggested that neointima formation elicited by unsaturated 
LPA is not mediated by the LPA receptors (GPCRs) expressed in blood-vessel walls [13]; however, 
topical application of unsaturated LPA species into the non-injured carotid artery of rodents induced 
arterial-wall remodeling [13], and this response required PPARγ. LPA and AGP have also been reported 
to be agonists of PPARγ and have been implicated in atherogenesis [10]. When AGP was infused to an 
injured carotid artery, neointimal thickening was augmented, whereas the TZD drug rosiglitazone 
attenuated neointimal thickening induced by mechanical injury. However, in a non-injury model, 
rosiglitazone induced neointima formation when applied intraluminally into the carotid artery [13]. Thus, 
AGP, but not rosiglitazone, increased injury-induced neointima formation, indicating that AGP-mediated 
PPARγ activation plays a role in vascular remodeling following vascular injury [13]. 
PPARγ is a member of the nuclear receptor gene family that plays a central role in the regulation 
of glucose and lipid homeostasis [36]. PPARγ plays a critical role in the cardiovascular system, and it is 
expressed in all cell types of the vessel wall, as well as in monocytes and macrophages [37]. PPARγ 
agonists promote adipocytic differentiation and stimulate the uptake of low-density lipoprotein by 
macrophages, leading to foam-cell formation in the arterial wall [38]. Considerable evidence suggests that 
oxidized phospholipids and fatty acids function as deleterious signaling molecules in the context of 
atherosclerosis lesion formation [39]. We recently determined that the production of cPA inhibits the 
transcription of PPARγ-target genes that normally drive adipocytic differentiation, lipid accumulation in 
macrophages, and arterial-wall remodeling; our recent work suggests that the endogenous LPA analog 
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cPA is a bona-fide second messenger and a physiological inhibitor of PPARγ [13]. However, the specific 
effects of diabetes on the function of the coronary endothelium are not well defined. 
In this study, we determined that the growth and migration of human coronary endothelial cells 
obtained from donors with type II diabetes and the suppressive effects of the phospholipid cPA require 
the inhibition of PPARγ (Fig.8). Furthermore, our results have demonstrated that, in HCAECs isolated 
from diabetes patients, which expressed PPARγ at high levels, VEGF production was elicited by AGP. 
We have shown that treatment with the PPARγ antagonist cPA diminished the synthesis of VEGF, which 
suggests that cPA inhibition of VEGF synthesis can affect the vessel wall by influencing endothelial cell 
growth and migration. Conversely, AGP, the high-affinity natural ligand of PPARγ [16], effectively 
increased VEGF mRNA expression and protein release. The VEGF promoter, however, does not contain 
the PPRE motif; thus, cPA appears to downregulate VEGF expression indirectly, and the reduction in the 
synthesis of mRNA and protein probably depends partly on the inhibition of the VEGF promoter. Several 
studies have reported increased levels of VEGF in the serum of patients with acute coronary syndrome 
[40]. Atherosclerosis is the most common type of heart disease and the leading cause of death resulting 
from cardiovascular diseases. In addition, previous report suggests that VEGF appears to play a central 
role in mediating diabetic endothelial dysfunction. [41]. Thus, the results of this study raise the possibility 
of using cPA as a lead compound to develop new treatments that act on PPARγ; however, further 
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Figure 1. Chemical structures of LPA, AGP, and cPA. It is made up of a glycerol backbone with a 
hydroxyl group, a phosphate group, and a long-chain saturated or unsaturated fatty acid. AGP is an alkyl-
ether analog of LPA. AGP shows a higher potency than LPA for the intracellular LPA receptor PPARγ. 
cPA is a naturally occurring acyl analog of LPA. cPA is a weak agonist of plasma membrane LPA 
receptors, whereas cPA is an inhibitor of PPARγ.   
 
Figure 2. Comparison of endogenous PPARγ expression in primary human coronary artery endothelial 
cells (HCAECs; from healthy donors) and D-HCAECs (from donors with type II diabetes). (A) Real-time 
PCR measurement of PPARγ1 and PPARγ2 mRNA expression in the tested cell lines. The PPARγ1 and 
PPARγ2 levels were normalized relative to β-actin and are expressed as mean ± SEM (n = 3), **p < 0.01. 
(B) Representative western blots showing the expression of PPARγ1 and PPARγ2 in HCAECs and D-
HCAECs from different donors. PPARγ proteins were separated by performing SDS-PAGE and then the 
levels were compared by visualizing immunoreactive bands by using an enhanced chemiluminescence 
reagent. Each lane was loaded with 10 μg of whole-cell lysate, and β-actin was used as the loading control. 
 
Figure 3. (A) Real-time PCR measurement of LPA1-6 mRNA expression in the tested cell lines. Total 
RNA was extracted from the cells and the expression level of each LPA receptor was determined using 
quantitative real-time PCR. The relative levels of LPA1-6 normalized to β-actin are expressed as mean ± 
SEM (n = 3), **p < 0.01.  (B) Real-time PCR measurement of the expression of PPARγ1 mRNA in 
HCAECs and D-HCAECs. Cells were incubated with 10 μM LPA (18:1) or cPA (18:1) for 24 h. The 
relative PPARγ1 mRNA levels, normalized to 18S rRNA, are expressed as mean ± SEM (n = 3), **p < 
0.01. (C) HCAECs and D-HCAECs were transfected with the PPRE-luc and CMV-β-galactosidase 
plasmids for 72 h and then treated with vehicle or the indicated PPARγ ligands for 24 h. The level of 
luciferase activity was measured in lysates of the treated cells and normalized to β-galactosidase activity. 
Data are presented as mean ± SEM (n = 5), **p < 0.01. (D) Transfection of LPA4 into D-HCAECs results 
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in LPA- and cPA-elicited Ca2+ transients. LPA4 transfected D-HCAECs and WT do not respond to cPA 
(up to 10 μM). Real-time PCR measurement of the overexpression of LPA4 in D-HCAECs (Right figure). 
Data are presented as mean ± SEM (n = 4), **p < 0.01. 
 
Figure 4. Effects of cPA on the proliferation of HCAECs and D-HCAECs under 0.1% BSA (fatty acid 
free ) medium. Time-dependent cell proliferation was measured using the Cell Counting Kit-8 at 0, 12, 24, 
and 48 h after incubation in EBSS medium alone (A) or in medium containing 10 μM cPA (B and C). 
Equal number of cells (1 × 104 cells/well) were seeded in 96-well plates and cultured overnight at 37°C in 
an incubator with 5% CO2. Subsequently, compounds were added to the medium, and cells were 
incubated for the indicated times. (D) Expression of PPARγ was knocked down in HCAECs and D-
HCAECs by using siRNAs. Time-dependent inhibition of cell growth was measured using the Cell 
Counting Kit-8 at 0, 12, 24, 48, and 72 h after siRNA transfection. Equal number of cells (1 × 104 
cells/well) were seeded in 96-well plates and cultured for 24 h at 37°C in an incubator with 5% CO2. Next, 
10 μL of the Cell Counting Kit-8 reagent was added to the medium and the cells were maintained for 2 h 
in the incubator (with 5% CO2). The amount of orange formazan dye generated was determined by 
measuring the absorbance at 450 nm in a microplate reader. Data are expressed as mean ± SEM (n = 3), 
**p < 0.01. 
 
Figure 5. Effect of cPA on the migration of HCAECs and D-HCAECs. (A) Migration of HCAECs and 
D-HCAECs was measured using a wound-healing assay. Images were captured after incubation for 0, 3, 
and 6 h by using an Olympus CKX31 inverted microscope (40 × magnification) equipped with a digital 
camera (MDCE-5B2, Shodensha, Osaka, Japan). (B) The migration of HCAECs and D-HCAECs co-
incubated with 10 μM LPA, cPA, and T0070907 was measured using a wound-healing assay. Images 
were captured after incubation for 0, 3, and 6 h as described in (A). Data from the wound-healing assays 
are presented as mean ± SEM (n = 3), **p < 0.01. Data are expressed as percentages of wound closure 
relative to the wound width at Time 0. Wound closure in untreated cells was regarded as 100%. (C) D-
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HCAEC cell migration increased after transfection with the siRNA targeting PPARγ but not the control 
siRNA.  
 
Figure 6. Real-time PCR measurement of VEGF mRNA expression in HCAECs and D-HCAECs. (A) 
HCAECs and D-HCAECs were treated with 10 μM cPA, LPA, or AGP for 20 h. The relative VEGF 
levels normalized to 18S rRNA are expressed as mean ± SEM (n = 3), **p < 0.01. (B) D-HCAECs were 
treated with indicated concentrations of cPA (18:1), AGP, or LPA (18:1) for 20 h. PCR was performed 
using specific primers for PSF. The relative VEGF levels normalized to 18S rRNA are expressed as mean 
± SEM (n = 3), **p < 0.01. (C) VEGF secretion in response to in vitro treatment with AGP. HCAECs and 
D-HCAECs were treated with AGP for 24 h, and VEGF secretion was assessed by performing ELISAs. 
Data from the VEGF assays are presented as mean ± SEM (n = 3), **p < 0.01. LPA but not cPA dose-
dependently increased VEGF release from D-HCAECs. The culture supernatants were collected after 
incubation for 24 h with DMSO (vehicle), LPA (18:1), AGP (1, 3, and 10 μM), or cPA (18:1) (1, 3, and 
10 μM). The VEGF levels in the supernatant were analyzed by performing ELISAs. (D) The effect of 
PPARγ ligands on the activity of the VEGF promoter, measured by performing luciferase assays on 
transiently transfected HCAECs and D-HCAECs. (E) cPA inhibited exogenously added VEGF enhanced 
D-HCAEC cell growth. D-HCAEC cells. An equal number of cells (1 × 104 cells/well) were seeded in 96-
well plates and cultured overnight at 37°C in an incubator with 5% CO2. Subsequently, VEGF (50 ng/mL) 
and cPA (10 μM) were added to the medium, and the cells were incubated for 12 h. The amount of orange 
formazan dye generated was determined by measuring the absorbance at 450 nm in a microplate reader. 
Data are expressed as mean ± SEM (n = 3), **p < 0.01. 
 
Figure 7. Down-regulation of VEGF inhibits the proliferation of D-HCAECs. (A) Expression of VEGF 
was knocked down in D-HCAECs. Total protein was extracted from untreated, control siRNA-, or VEGF 
siRNA-transfected cells. Forty-eight hours later, whole-cell lysates were subjected to western blot 
analysis for VEGF. Incubation with an anti-β-actin antibody was used as a protein-loading control. (B) 
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The effect of siRNA on mRNA expression in D-HCAECs. The efficiency of VEGF knockdown was 
calculated to be 80% by real-time quantitative RT-PCR. Data are expressed as mean ± SEM (n = 3), **p 
< 0.01. (C) VEGF secretion in response to in vitro treatment with AGP (1, 3, and 10 μM). HCAECs and 
D-HCAECs were treated with AGP for 24 h, and VEGF secretion was assessed by performing ELISAs. 
Data from the VEGF assays are presented as mean ± SEM (n = 3), **p < 0.01. (D) VEGF-siRNA-
transfected D-HCAEC cells were inhibited cell growth promotion. An equal number of cells (1 × 104 
cells/well) were seeded in 96-well plates and cultured overnight at 37°C in an incubator with 5% CO2. 
Subsequently, DMSO (vehicle), 10 μM AGP (18:1), or 10 μM cPA (18:1) were added to the medium, and 
the cells were incubated for 24 h. The amount of orange formazan dye generated was determined by 
measuring the absorbance at 450 nm in a microplate reader. Data are expressed as mean ± SEM (n = 3), 
**p < 0.01. (E) Effect of cPA on mRNA expression and production of inflammatory cytokines 
To measure mRNA expression, D-HCAEC were cultured with 10 µM cPA for 24 h in the presence or 
absence of 10 µM AGP. mRNA levels of each gene were determined by quantitative real-time PCR. Data 
represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs. vehicle-
treated controls). To measure IL-6, and IL-8 concentrations in the culture media of D-HCAEC, After 24 h 
incubation, culture media were collected, and IL-6, and IL-8 concentrations were determined by ELISA. 
Data represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs. 
vehicle-treated controls). 
 
Figure 8.  Schematic representation of the proposed mechanism of cPA action in D-HCAECs.  
After treatment with AGP, cell growth and migration was induced in D-HCAECs, obtained from donors 
with type II diabetes. Moreover, addition of cPA suppressed the AGP-elicited growth and migration in D-
HCAECs. AGP increased VEGF secretion from the D-HCAECs, and this event was attenuated by cPA. 
These results suggest that cPA suppresses VEGF-stimulated growth and migration in D-HCAECs. 
 








